Recipharm and Synthonics Join Forces to Promote Novel Drug Delivery Technology
Recipharm Pharmaceutical Development AB and Synthonics, Inc. announce today the formation of a Joint Promotion Agreement. The contract, the first of its kind to be entered into between the two companies, will provide Recipharm customers full access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds.
Welcome to Synthonics
We are a specialty pharmaceutical company focused on the discovery, development and licensing of drugs that incorporate our proprietary metal coordination chemistry. Metal coordination entails attaching a pharmaceutically acceptable metal, such as zinc, bismuth or magnesium, to a known pharmaceutical agent to create a new and more effective drug. The addition of the metal changes the way the drug is absorbed or delivered without altering the action of the underlying drug.
Metal coordination offers tremendous flexibility, allowing us to "dial in" the desired pharmacokinetics by varying the metals used and the manner in which they are attached. In its simplest application, metal coordination improves a drug's absorption and delivery without changing the way the drug works once delivered. Metal coordination can also be used to extend or control a drug’s release or to prevent a drug's systemic absorption.
Unlike salts, metal coordinated pharmaceuticals are generally patentable as new compositions of matter under U.S. patent laws--even if the parent drug is already well known. We hold four U.S. patents and have dozens of additional claims pending.
Metal coordination is a platform technology with broad application that can be profitably applied both to already marketed drugs and to drugs under development. We have drug discovery and development programs underway on a handful of molecules. In addition, we partner with large pharmaceutical companies to enhance their pipeline and marketed products.